SLC46A3 is a lysosomal proton-coupled steroid conjugate and bile acid transporter involved in transport of active catabolites of T-DM1

Antibody–drug conjugates (ADCs) represent a new class of cancer therapeutics that enable targeted delivery of cytotoxic drugs to cancer cells. Although clinical efficacy has been demonstrated for ADC therapies, resistance to these conjugates may occur. Recently, SLC46A3, a lysosomal membrane protein...

Descripción completa

Detalles Bibliográficos
Autores principales: Tomabechi, Ryuto, Kishimoto, Hisanao, Sato, Taeka, Saito, Naoki, Kiyomiya, Keisuke, Takada, Tappei, Higuchi, Kei, Shirasaka, Yoshiyuki, Inoue, Katsuhisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Biological, Health, and Medical Sciences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9896951/
https://www.ncbi.nlm.nih.gov/pubmed/36741448
http://dx.doi.org/10.1093/pnasnexus/pgac063

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9896951/
https://www.ncbi.nlm.nih.gov/pubmed/36741448
http://dx.doi.org/10.1093/pnasnexus/pgac063

Ejemplares similares